We are live on ! Find out more
SCM

Soleus Capital Management Portfolio holdings

AUM $2.47B
1-Year Est. Return 115.63%
This Fund
S&P 500
This Quarter Est. Return
+18.23%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$1.29B
AUM Growth
+$158M
Cap. Flow
+$36.7M
Cap. Flow %
2.84%
Top 10 Hldgs %
39.6%
Holding
109
New
17
Increased
24
Reduced
36
Closed
22

Top Buys

Rank Stock Value
1
GRFS
Grifois
GRFS
+$36.8M
2
SNY icon
Sanofi
SNY
+$29.7M
3
QDEL icon
QuidelOrtho
QDEL
+$27.8M
4
KRYS icon
Krystal Biotech
KRYS
+$17.5M
5
LLY icon
Eli Lilly
LLY
+$17.4M

Top Sells

Rank Stock Value
1
TGTX icon
TG Therapeutics
TGTX
+$24.3M
2
NRIX icon
Nurix Therapeutics
NRIX
+$22.4M
3
PEN icon
Penumbra
PEN
+$22.2M
4
HUM icon
Humana
HUM
+$16.6M
5
GSK icon
GSK
GSK
+$15.4M

Sector Composition

Rank Sector Weight
1 Healthcare 93.11%
2 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NVCR icon
101
NovoCure
NVCR
$1.83B
– –
-108,900
Closed -$1.87M
ORIC icon
102
Oric Pharmaceuticals
ORIC
$1.34B
– –
-163,000
Closed -$1.15M
PEN icon
103
Penumbra
PEN
$12.8B
– –
-123,450
Closed -$22.2M
RCEL icon
104
Avita Medical
RCEL
$146M
– –
-267,000
Closed -$2.11M
SKIN icon
105
SkinHealth Systems
SKIN
$99.5M
– –
-1,604,718
Closed -$3.08M
TEVA icon
106
Teva Pharmaceuticals
TEVA
$40.6B
– –
-586,499
Closed -$9.53M
WGS icon
107
GeneDx Holdings
WGS
$2.08B
– –
-87,000
Closed -$2.27M
XERS icon
108
Xeris Biopharma Holdings
XERS
$1.27B
– –
-62,083
Closed -$140K
XFOR icon
109
X4 Pharmaceuticals
XFOR
$393M
– –
-135,033
Closed -$2.35M
1 2 3 4
5

Similar funds

TW
Trajan Wealth Scottsdale, Arizona $2.48B AUM 17.44% 1-Year Est. Return
M
Mirova Paris, France $2.46B AUM 11.42% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $2.48B AUM 72.25% 1-Year Est. Return
FFA
First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return
Q
QVR San Francisco, California $2.49B AUM 48.58% 1-Year Est. Return
SIM
Stratos Investment Management Beachwood, Ohio $2.49B AUM 17.24% 1-Year Est. Return
QT
Quantbot Technologies New York $2.44B AUM 17.13% 1-Year Est. Return

Soleus Capital Management's Q3 2024 Portfolio in Review

As of Q3 2024, Soleus Capital Management held 109 positions worth $1.29B, up 14% from $1.13B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Soleus Capital Management's Q3 2024 filing shows 17 new, 24 increased, 36 reduced and 22 closed positions. Its largest new stake was Grifois: 4,521,703 shares worth $40.2M. The largest sale was TG Therapeutics, an estimated $24.3M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 100% a quarter earlier, followed by Consumer Staples.

  • Soleus Capital Management's largest Q3 2024 buy was Grifois: 4,521,703 shares worth $40.2M.
  • Soleus Capital Management added most to Sanofi in Q3 2024, an estimated $29.7M increase.
  • Soleus Capital Management's biggest Q3 2024 reduction was TG Therapeutics, cutting an estimated $24.3M.
  • Soleus Capital Management fully exited Penumbra in Q3 2024, selling an estimated $22.2M.
  • Soleus Capital Management's ten largest holdings make up 40% of its $1.29B portfolio in Q3 2024.
  • Soleus Capital Management opened 17 new positions and closed 22 in Q3 2024.
  • Soleus Capital Management's portfolio value rose 14% quarter-over-quarter to $1.29B.

Based on Soleus Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.